Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Kinesio Taping for Upper Trapezius Myofascial Trigger Points

24 de agosto de 2026 actualizado por: Alev Atıgan, Pamukkale University

Effects of Kinesio Taping on Pain, Pressure Pain Threshold, Trapezius Muscle Thickness, and Strain Elastography in Patients With Upper Trapezius Myofascial Trigger Points: A Randomized Sham-Controlled Trial

Myofascial pain syndrome is one of the most common causes of musculoskeletal pain, and the upper trapezius is the muscle most frequently affected in the neck and shoulder region. Kinesio taping is a non-invasive, painless and low-cost method that is increasingly used in the treatment of myofascial trigger points, but its true therapeutic effect beyond placebo has not been clearly established.

The purpose of this randomized, sham-controlled trial is to evaluate the effectiveness of kinesio taping applied with the muscle inhibition technique on myofascial trigger points of the upper trapezius muscle. Forty patients with an active myofascial trigger point in the upper trapezius will be randomly assigned in a 1:1 ratio to receive either therapeutic kinesio taping or sham taping (20 patients per group). Both groups will receive four applications over two weeks (twice weekly). The primary outcome is the pressure pain threshold measured with a digital algometer. Secondary outcomes are pain intensity, trapezius muscle thickness measured by B-mode ultrasonography, and muscle stiffness assessed by strain elastography. All outcomes are assessed at baseline, on day 3, and at the end of the two-week treatment period.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

Myofascial pain syndrome is characterized by hyperirritable nodules located within taut bands of skeletal muscle, known as myofascial trigger points. The upper trapezius is the most commonly involved muscle in the neck and shoulder girdle, and trigger points in this region are an important cause of neck pain, restricted mobility and loss of productivity.

Kinesio taping has become increasingly popular in the management of myofascial trigger points because it is non-invasive, painless, inexpensive and has few adverse effects. Systematic reviews and meta-analyses suggest that kinesio taping reduces pain intensity and improves pressure pain threshold and range of motion in myofascial pain syndrome. However, the taping techniques used across studies differ substantially. Two techniques predominate: the space correction technique, in which strips are applied over the trigger point in a star-shaped pattern, and the muscle inhibition technique, in which a single I-strip is applied along the muscle fibres from insertion to origin with low tension. A trial directly comparing these two techniques found no significant difference between them, whereas a sham-controlled trial found that the space correction technique was not superior to sham at 72 hours. Studies using the inhibition technique have reported significant improvements in pressure pain threshold. Because the inhibition technique is mechanistically aimed at reducing muscle tone and is supported by stronger evidence, it was selected for this trial.

In addition, outcome measures in previous studies have been largely subjective. Pressure algometry provides a quantitative measure of the mechanical sensitivity of the trigger point, while B-mode ultrasonography allows measurement of muscle thickness and ultrasound elastography allows objective assessment of tissue stiffness. Strain elastography with calculation of the strain ratio has shown good reliability in patients with upper trapezius myofascial pain syndrome and can differentiate active trigger points, latent trigger points and control sites.

To the best of our knowledge, no sham-controlled randomized trial has evaluated kinesio taping of upper trapezius myofascial trigger points using pressure pain threshold as the primary outcome together with muscle thickness and strain elastography as objective secondary outcomes. A sham-controlled design was chosen because sham taping alone may produce a substantial placebo response, and only a sham comparator can isolate the true therapeutic effect.

In the intervention group, a single I-shaped kinesio tape strip will be applied from insertion to origin along the upper trapezius with 15-25% tension while the muscle is held in a stretched position. In the sham group, an identical tape of the same brand, colour and size will be applied to the same region without therapeutic tension and with the neck in a neutral position, so that the skin convolutions responsible for the therapeutic effect are not produced. Both groups will receive four applications over two weeks (twice weekly); at each session the existing tape is removed and a new tape applied, so the tape remains on the skin continuously throughout the treatment period.

Patients will be randomly allocated in a 1:1 ratio using a computer-generated random number list. The study is single-blind: the practitioner applying the tape cannot be blinded due to the nature of the intervention and therefore takes no part in any assessment. All pain, pressure pain threshold and ultrasonographic measurements will be performed by a researcher blinded to group allocation, after tape removal.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Denizli, Turquía (Türkiye)
        • Pamukkale University, Faculty of Medicine, Department of Physical Medicine and Rehabilitation

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Age between 18 and 65 years
  • At least one active myofascial trigger point in the upper trapezius muscle diagnosed on clinical examination according to the criteria of Travell and Simons
  • Neck and/or shoulder pain lasting at least 3 months
  • Able to understand the procedures, benefits and possible adverse effects
  • Able to provide written informed consent

Exclusion Criteria:

  • Diagnosis of fibromyalgia syndrome
  • Cervical disc herniation, radiculopathy or myelopathy
  • History of cervical or shoulder surgery
  • History of trauma, fracture or structural deformity of the neck region
  • Inflammatory rheumatic disease, malignancy or serious systemic disease
  • Neurological disease or peripheral neuropathy
  • Kinesio taping to the trigger point, injection, dry needling or physical therapy to the neck region within the previous 6 months
  • Use of analgesics, muscle relaxants or non-steroidal anti-inflammatory drugs within the previous week
  • Active skin lesion, wound, dermatological disease or known allergy to tape at the application site
  • Pregnancy or lactation

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Kinesio Taping
Therapeutic kinesio taping applied to the myofascial trigger point of the upper trapezius using the muscle inhibition technique. A single I-shaped strip is applied from insertion to origin along the muscle fibres with 15-25% tension while the muscle is held in a stretched position (shoulder depressed, neck in contralateral lateral flexion and rotation). Four applications over two weeks (twice weekly).
Elastic therapeutic tape applied over the upper trapezius myofascial trigger point using the muscle inhibition technique. A single I-shaped strip is applied from insertion to origin along the muscle fibres with 15-25% tension while the muscle is held in a stretched position. The tape is renewed at each session and remains on the skin continuously throughout the two-week treatment period (four applications, twice weekly).
Comparador falso: Sham Kinesio Taping
Sham taping using tape of identical brand, colour and size, applied by the same practitioner to the same anatomical region, with no therapeutic tension (0% tension) and with the neck in a neutral position, so that no skin convolutions are produced. Four applications over two weeks (twice weekly), identical in frequency and duration to the intervention group.
Tape of identical brand, colour and size applied over the same anatomical region without therapeutic tension (0% tension) and with the neck in a neutral position, so that the skin convolutions responsible for the therapeutic effect are not produced. The tape is renewed at each session and remains on the skin continuously throughout the two-week treatment period (four applications, twice weekly).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Pressure Pain Threshold (PPT) of the upper trapezius trigger point
Periodo de tiempo: Baseline, day 3, and end of week 2
Pressure pain threshold measured over the marked trigger point with a digital algometer with the participant prone and the muscle relaxed. The probe is applied perpendicular to the trigger point and pressure is increased at approximately 1 kg/cm2/s. The participant reports verbally when the pressure first becomes painful. The mean of three measurements taken at least 30 seconds apart is used. An increase indicates reduced trigger point sensitivity.
Baseline, day 3, and end of week 2

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in pain intensity measured by Visual Analogue Scale (VAS)
Periodo de tiempo: Baseline, day 3, and end of week 2
Pain intensity assessed on a 10 cm horizontal visual analogue scale anchored at 0 (no pain) and 10 (unbearable pain). The marked distance is measured with a ruler.
Baseline, day 3, and end of week 2
Change in upper trapezius muscle thickness measured by B-mode ultrasonography
Periodo de tiempo: Baseline, day 3, and end of week 2
Muscle thickness measured with a diagnostic ultrasound device using an 8-13 MHz linear probe placed parallel to the muscle fibres over the marked region. On a clear longitudinal image of the upper trapezius, the shortest vertical distance between the superior and inferior hyperechoic borders of the muscle at the centre of the image is recorded.
Baseline, day 3, and end of week 2
Change in muscle stiffness measured by strain elastography (strain ratio)
Periodo de tiempo: Baseline, day 3, and end of week 2
Strain elastography performed with the participant prone and the probe parallel to the muscle fibres at the midpoint between the C7 spinous process and the acromion. Constant light probe pressure is maintained using the pressure feedback indicator. Two regions of interest are placed: a reference region in subcutaneous fat (approximately 2x5 mm) and a target region over the trigger point (approximately 3x8 mm). The strain ratio is calculated as the muscle region value divided by the fat region value and is inversely related to tissue stiffness. The mean of three measurements recorded at end-expiration is used.
Baseline, day 3, and end of week 2

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Alev ATIGAN, Assistant Professor, Pamukkale University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de agosto de 2026

Finalización primaria (Estimado)

1 de octubre de 2026

Finalización del estudio (Estimado)

1 de octubre de 2026

Fechas de registro del estudio

Enviado por primera vez

24 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

24 de agosto de 2026

Publicado por primera vez (Actual)

27 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

27 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • E-60116787-020-916157

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .